CeriBell, Inc. (NASDAQ:CBLL – Get Free Report) Director Joseph Michael Taylor sold 13,095 shares of the firm’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $23.40, for a total value of $306,423.00. Following the completion of the transaction, the director owned 48,478 shares in the company, valued at approximately $1,134,385.20. This trade represents a 21.27% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Joseph Michael Taylor also recently made the following trade(s):
- On Thursday, June 11th, Joseph Michael Taylor sold 5,500 shares of CeriBell stock. The stock was sold at an average price of $18.41, for a total value of $101,255.00.
CeriBell Price Performance
NASDAQ CBLL traded up $0.08 during mid-day trading on Friday, hitting $23.33. The stock had a trading volume of 135,920 shares, compared to its average volume of 342,175. The firm’s 50 day moving average is $18.83 and its 200 day moving average is $19.08. The company has a debt-to-equity ratio of 0.14, a current ratio of 10.44 and a quick ratio of 10.01. The stock has a market capitalization of $895.21 million, a price-to-earnings ratio of -13.21 and a beta of 0.81. CeriBell, Inc. has a twelve month low of $10.85 and a twelve month high of $24.33.
Analyst Ratings Changes
A number of research analysts have weighed in on the stock. Weiss Ratings lowered shares of CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 14th. Canaccord Genuity Group increased their price target on CeriBell from $25.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday. Finally, BTIG Research reiterated a “buy” rating and set a $28.00 price objective on shares of CeriBell in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $22.00.
Read Our Latest Research Report on CBLL
Institutional Trading of CeriBell
Institutional investors have recently made changes to their positions in the company. JPMorgan Chase & Co. lifted its holdings in CeriBell by 6,424.8% in the second quarter. JPMorgan Chase & Co. now owns 380,003 shares of the company’s stock valued at $7,117,000 after acquiring an additional 374,179 shares during the last quarter. Rhumbline Advisers raised its position in CeriBell by 109.9% in the second quarter. Rhumbline Advisers now owns 32,806 shares of the company’s stock valued at $614,000 after purchasing an additional 17,177 shares during the period. New York State Common Retirement Fund grew its holdings in shares of CeriBell by 148.6% during the 2nd quarter. New York State Common Retirement Fund now owns 8,700 shares of the company’s stock worth $163,000 after purchasing an additional 5,200 shares during the period. Quantbot Technologies LP increased its position in shares of CeriBell by 70.3% during the 2nd quarter. Quantbot Technologies LP now owns 15,504 shares of the company’s stock worth $290,000 after purchasing an additional 6,401 shares during the last quarter. Finally, Invesco Ltd. acquired a new stake in shares of CeriBell during the 2nd quarter worth about $197,000.
About CeriBell
CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.
The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.
Featured Articles
- Five stocks we like better than CeriBell
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Receive News & Ratings for CeriBell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CeriBell and related companies with MarketBeat.com's FREE daily email newsletter.
